

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>10/522,207</td> </tr> <tr> <td>Filing Date</td> <td>July 17, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Mazher Hussein Ali et al.</td> </tr> <tr> <td>Art Unit</td> <td>1625</td> </tr> <tr> <td>Examiner Name</td> <td>Celia C. Chang</td> </tr> </table>		Application Number	10/522,207	Filing Date	July 17, 2003	First Named Inventor	Mazher Hussein Ali et al.	Art Unit	1625	Examiner Name	Celia C. Chang
Application Number	10/522,207														
Filing Date	July 17, 2003														
First Named Inventor	Mazher Hussein Ali et al.														
Art Unit	1625														
Examiner Name	Celia C. Chang														
Sheet	1	of	1	Attorney Docket No: AC-22-US											

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DRAYER et al., Clinical and Pharmacology and Therapeutics, 1986.	
		HUTT and O'GRADY, Drug Chirality, 1996.	
		LIN and LU et al., Role of Pharmacokinetics and Metabolism in Discovery and Development, 1997.	
		TESTA et al., Racemates Versus Enantiomers in Drug Development, 1990.	

EXAMINER

DATE CONSIDERED